Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo

L. Bello, G. Carrabba, C. Giussani, V. Lucini, F. Cerutti, F. Scaglione, J. Landré, M. Pluderi, G. Tomei, R. Villani, R. S. Carroll, P. Mc L Black, A. Bikfalvi

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

This study evaluates the efficacy of the combination of an antiangiogenic drug and conventional chemotherapeutics for the treatment of experimental human gliomas. As an antiangiogenic, we used recombinant human PEX, a fragment of matrix metalloproteinase-2 that we have previously shown to have a significant antimitotic, anti-invasive, and antiangiogenic properties against human glioblastoma in vitro and in vivo. We used carboplatin and etoposide as the two chemotherapeutic drugs routinely used in our institution (Ospedale Maggiore de Milano) for the treatment of malignant gliomas. Conventional chemotherapeutic drugs were administered at high dose or at a low and semicontinuous regimen. Combined treatment of high-dose chemotherapy and PEX did not produce an improvement of survival in comparison with chemotherapy alone, but it was associated with a decrease in tumor volume, vascularity, and proliferative index and an increased apoptosis. All of these animals experienced severe side effects. The longest survival was documented in animals submitted to low and semicontinuous chemotherapy and antiangiogenic treatment. This regimen was associated with no side effects, marked decrease in tumor volume, vascularity, and proliferative index, and an increased apoptosis. Our data suggest that low-dose chemotherapy in combination with PEX can be successfully used against human malignant glioma in vivo.

Original languageEnglish
Pages (from-to)7501-7506
Number of pages6
JournalCancer Research
Volume61
Issue number20
Publication statusPublished - Oct 15 2001

Fingerprint

Glioma
Drug Therapy
Growth
Tumor Burden
Pharmaceutical Preparations
Apoptosis
Antimitotic Agents
Survival
Carboplatin
Matrix Metalloproteinase 2
Etoposide
Drug Combinations
Therapeutics
Glioblastoma
Combination Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bello, L., Carrabba, G., Giussani, C., Lucini, V., Cerutti, F., Scaglione, F., ... Bikfalvi, A. (2001). Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Research, 61(20), 7501-7506.

Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. / Bello, L.; Carrabba, G.; Giussani, C.; Lucini, V.; Cerutti, F.; Scaglione, F.; Landré, J.; Pluderi, M.; Tomei, G.; Villani, R.; Carroll, R. S.; Black, P. Mc L; Bikfalvi, A.

In: Cancer Research, Vol. 61, No. 20, 15.10.2001, p. 7501-7506.

Research output: Contribution to journalArticle

Bello, L, Carrabba, G, Giussani, C, Lucini, V, Cerutti, F, Scaglione, F, Landré, J, Pluderi, M, Tomei, G, Villani, R, Carroll, RS, Black, PML & Bikfalvi, A 2001, 'Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo', Cancer Research, vol. 61, no. 20, pp. 7501-7506.
Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Research. 2001 Oct 15;61(20):7501-7506.
Bello, L. ; Carrabba, G. ; Giussani, C. ; Lucini, V. ; Cerutti, F. ; Scaglione, F. ; Landré, J. ; Pluderi, M. ; Tomei, G. ; Villani, R. ; Carroll, R. S. ; Black, P. Mc L ; Bikfalvi, A. / Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. In: Cancer Research. 2001 ; Vol. 61, No. 20. pp. 7501-7506.
@article{0e8ce62378094252998ea620b726656c,
title = "Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo",
abstract = "This study evaluates the efficacy of the combination of an antiangiogenic drug and conventional chemotherapeutics for the treatment of experimental human gliomas. As an antiangiogenic, we used recombinant human PEX, a fragment of matrix metalloproteinase-2 that we have previously shown to have a significant antimitotic, anti-invasive, and antiangiogenic properties against human glioblastoma in vitro and in vivo. We used carboplatin and etoposide as the two chemotherapeutic drugs routinely used in our institution (Ospedale Maggiore de Milano) for the treatment of malignant gliomas. Conventional chemotherapeutic drugs were administered at high dose or at a low and semicontinuous regimen. Combined treatment of high-dose chemotherapy and PEX did not produce an improvement of survival in comparison with chemotherapy alone, but it was associated with a decrease in tumor volume, vascularity, and proliferative index and an increased apoptosis. All of these animals experienced severe side effects. The longest survival was documented in animals submitted to low and semicontinuous chemotherapy and antiangiogenic treatment. This regimen was associated with no side effects, marked decrease in tumor volume, vascularity, and proliferative index, and an increased apoptosis. Our data suggest that low-dose chemotherapy in combination with PEX can be successfully used against human malignant glioma in vivo.",
author = "L. Bello and G. Carrabba and C. Giussani and V. Lucini and F. Cerutti and F. Scaglione and J. Landr{\'e} and M. Pluderi and G. Tomei and R. Villani and Carroll, {R. S.} and Black, {P. Mc L} and A. Bikfalvi",
year = "2001",
month = "10",
day = "15",
language = "English",
volume = "61",
pages = "7501--7506",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo

AU - Bello, L.

AU - Carrabba, G.

AU - Giussani, C.

AU - Lucini, V.

AU - Cerutti, F.

AU - Scaglione, F.

AU - Landré, J.

AU - Pluderi, M.

AU - Tomei, G.

AU - Villani, R.

AU - Carroll, R. S.

AU - Black, P. Mc L

AU - Bikfalvi, A.

PY - 2001/10/15

Y1 - 2001/10/15

N2 - This study evaluates the efficacy of the combination of an antiangiogenic drug and conventional chemotherapeutics for the treatment of experimental human gliomas. As an antiangiogenic, we used recombinant human PEX, a fragment of matrix metalloproteinase-2 that we have previously shown to have a significant antimitotic, anti-invasive, and antiangiogenic properties against human glioblastoma in vitro and in vivo. We used carboplatin and etoposide as the two chemotherapeutic drugs routinely used in our institution (Ospedale Maggiore de Milano) for the treatment of malignant gliomas. Conventional chemotherapeutic drugs were administered at high dose or at a low and semicontinuous regimen. Combined treatment of high-dose chemotherapy and PEX did not produce an improvement of survival in comparison with chemotherapy alone, but it was associated with a decrease in tumor volume, vascularity, and proliferative index and an increased apoptosis. All of these animals experienced severe side effects. The longest survival was documented in animals submitted to low and semicontinuous chemotherapy and antiangiogenic treatment. This regimen was associated with no side effects, marked decrease in tumor volume, vascularity, and proliferative index, and an increased apoptosis. Our data suggest that low-dose chemotherapy in combination with PEX can be successfully used against human malignant glioma in vivo.

AB - This study evaluates the efficacy of the combination of an antiangiogenic drug and conventional chemotherapeutics for the treatment of experimental human gliomas. As an antiangiogenic, we used recombinant human PEX, a fragment of matrix metalloproteinase-2 that we have previously shown to have a significant antimitotic, anti-invasive, and antiangiogenic properties against human glioblastoma in vitro and in vivo. We used carboplatin and etoposide as the two chemotherapeutic drugs routinely used in our institution (Ospedale Maggiore de Milano) for the treatment of malignant gliomas. Conventional chemotherapeutic drugs were administered at high dose or at a low and semicontinuous regimen. Combined treatment of high-dose chemotherapy and PEX did not produce an improvement of survival in comparison with chemotherapy alone, but it was associated with a decrease in tumor volume, vascularity, and proliferative index and an increased apoptosis. All of these animals experienced severe side effects. The longest survival was documented in animals submitted to low and semicontinuous chemotherapy and antiangiogenic treatment. This regimen was associated with no side effects, marked decrease in tumor volume, vascularity, and proliferative index, and an increased apoptosis. Our data suggest that low-dose chemotherapy in combination with PEX can be successfully used against human malignant glioma in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0035887463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035887463&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 7501

EP - 7506

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 20

ER -